| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Tandem Diabetes Care, Inc.$15.41
+0.04 (+0.26%)
D 24Pipeline Score MedTech · Commercial
Market Cap
1.03 B
EPS
-1.40
P/E Ratio
-
Value Trade
42.77 M
SEC Financials
Q1 2026Dilution Risk
Revenue
247.22 M
R&D Expenses
46.03 M
Operating CF
11.05 M
Total Assets
1.15 B
Total Liabilities
1.02 B
Equity
132.40 M
D/E Ratio
12,345
9.63 %
Week
-26.24 %
1 Month
-34.21 %
3 Month
-23.18 %
6 Month
-82.34 %
5 Year
-92.33 %
All Time
Cash Data
Cash Position
570.26 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.32 M
52 Week Range
9.98 - 29.65
% held by Insiders
7.33 %
% held by Institutions
115.94 %
Enterprise Value
1.19 B
Total Shares
68.54 M
Short %
17.09 %
Float Shares
67.85 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tandem Diabetes Care, Inc.
2Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
Event history 1
Jul 1, 2026
▲Product LaunchPost-Market
Launch of t:slim X2 insulin pump compatibility with Abbott FreeStyle Libre 3 Plus sensor in five international markets
diabetessource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $29M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 22%
Micro Cap (rank 712 of 911)
Percentile RankTandem Diabetes Care, Inc. faces pipeline headwinds (24/100), with $73M risk-adjusted pipeline value, led by tozadenant in N/A, as Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tozadenant Small molecule | N/A, as Healthy Volunteers | Phase 1 | NCT02240290 | 15% | $73M | COMPLETED | 6 | - | - | Oct 1, 2013 | - | Aug 4, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TNDM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TNDM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TNDMTandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care has announced the launch of the t:slim X2 insulin pump's compatibility with the Abbott FreeStyle Libre 3 Plus sensor. This development marks a significant step in diabetes management, as it will be available in five international markets. The integration aims to improve user experience and enhance diabetes care.
Read more →TNDMTandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
Tandem Diabetes Care has scheduled the announcement of its financial results for the second quarter of 2026 on August 6, 2026. This announcement is part of the company's regular reporting schedule. Further details regarding the financial performance will be provided at that time.
Read more →TNDMTANDEM DIABETES CARE, INC. RECONCILIATION OF GAAP VERSUS NON-GAAP FINANCIAL RESULTS Table D (Unaudited) ($'s in thousands) Three Months Ended
Tandem Diabetes Care, Inc. reported its financial results for Q1 2026, highlighting record shipments and sales of insulin delivery systems. The company's sales reached $247.2 million, with significant growth in the U.S. market. Gross margins improved to 55% compared to the previous year. Despite these positive developments, Tandem still faced an operating loss of $17.4 million. The company reaffirmed its financial guidance for the year, estimating sales between $1.065 billion to $1.085 billion.
Read more →TNDMTandem Diabetes Care Announces First Quarter 2026 Financial Results
Tandem Diabetes Care has announced its financial results for the first quarter of 2026. The report includes key metrics and insights into the company's performance during this period. Specific details regarding revenue, expenses, and future outlook were not disclosed in the provided text.
Read more →TNDMTandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Tandem Diabetes Care is set to announce its financial results for the first quarter of 2026 on May 7, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will be disclosed during the announcement.
Read more →TNDM▼ -9.9%on this news
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Tandem Diabetes Care, Inc. regarding possible securities fraud, following a significant drop in the company's stock value. This decline was triggered by news of a malfunction in several insulin pumps that could lead to severe health risks such as hyperglycemia. Affected customers were notified before the public announcement, raising concerns about the company's transparency. Investors are encouraged to contact the law firm for potential claims related to this issue.
Read more →TNDMTandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Tandem Diabetes Care announced the pricing of $265 million in Convertible Senior Notes due 2032, up from an initial $200 million offering. The proceeds will be used for corporate purposes, including capped call transactions to offset potential dilution. The sale is expected to close on February 27, 2026, subject to customary conditions.
Read more →TNDM▲ +15%on this newsshared move
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Tandem Diabetes Care, Inc. announced a proposed private placement of $200 million in convertible senior notes due 2032, subject to market conditions. The company will also grant initial purchasers an option for an additional $30 million in notes. Proceeds are expected to fund capped call transactions and support general corporate purposes. The notes will be unsecured obligations of Tandem with interest payable semiannually, and may convert into cash, shares, or a combination thereof.
Read more →TNDM(4) In the first quarter of 2025, the Company included an adjustment for IPR D expense in its non-GAAP financials and provided guidance based on this practice. Beginning in the second quarter of 2025, the Company no long
Tandem Diabetes Care, Inc. reported strong financial results for Q4 2025 and provided 2026 guidance. Sales reached a record $290.4 million, bolstered by significant operational improvements and product innovations. Despite achieving a positive adjusted EBITDA and a record gross margin of 58%, the company faced a net loss and operating losses for the year. Looking ahead, Tandem aims to grow shipments and navigate a new pay-as-you-go pharmacy model in 2026.
Read more →TNDMTandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors
Tandem Diabetes Care has appointed Sandra Beaver to its Board of Directors, effective November 7, 2025. Ms. Beaver, an independent director, will contribute her extensive experience in finance and healthcare, serving on both the Audit Committee and Cybersecurity and Data Oversight Committee. The leadership of Tandem highlighted her dynamic capabilities, expecting her to facilitate the company’s growth and market expansion. Beaver's background includes roles at Lyra Health and Evolus, making her a valuable addition to the team as they focus on innovative diabetes solutions.
Read more →TNDMTandem Diabetes Care, Inc. (TNDM) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps. On August 7, 2025, the company announced that this malfunction could trigger discontinuation of insulin delivery, posing health risks to users. As a result, the stock price plummeted by nearly 20%, affecting shareholders. The Law Offices of Howard G. Smith are reaching out to investors who may have incurred losses as a result.
Read more →TNDM▼ -9.9%on this news
Tandem Diabetes Care Inc. (TNDM) - Product Pipeline Analysis Report 2025
Tandem Diabetes Care Inc. has been highlighted in the "Product Pipeline Analysis, 2025 Update" report, showcasing its commitment to revolutionizing diabetes management through advanced technology. The report details Tandem's innovative products like the Tandem Mobi system and t:slim X2 insulin pump, both utilizing Control-IQ technology. It also presents insights into the company’s pipeline products, clinical trials, and competitive landscape, aimed at aiding stakeholders in making informed decisions. The report underscores the company's extensive resources in education, marketing, and strategic planning.
Read more →TNDM▼ -5%on this news· ran to -33% by day 3shared move
TANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results Table D (Unaudited) ($'s in thousands) Three Months Ended June 30, Six Months Ended
Tandem Diabetes Care, Inc. reported its second quarter 2025 financial results with record sales of $240.7 million, reflecting growth in both the U.S. and international markets. The company also provided guidance expecting total sales to reach $1 billion for the full year. Despite this growth, Tandem experienced increased operating and net losses compared to the previous year. The introduction of a new insulin pump with cutting-edge technology could further enhance its market position.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table D ($'s in thousands) Three Months Ended
Tandem Diabetes Care, Inc. reported its financial results for the first quarter of 2025, showcasing a significant growth with worldwide sales reaching $234.4 million, a 22% increase year-over-year. The company's adjusted EBITDA margin improved, and 30% of U.S. lives are now covered through pharmacy benefits for Tandem Mobi. However, the operating loss expanded to $120.9 million and net loss also increased to $130.6 million compared to the previous year. Despite these losses, the company reaffirms its full-year guidance with anticipated sales between $997 million and $1.007 billion.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table D ($'s in thousands) Three Months Ended December 31, Twelve Months Ended
Tandem Diabetes Care, Inc. reported strong financial performance for the fourth quarter and full year 2024, with record sales and significant growth in pump shipments. The company achieved a 44% increase in worldwide GAAP sales in Q4 2024 compared to the previous year, alongside successful new FDA clearances. Despite these positive results, Tandem faced operational losses and anticipates challenges related to their expansion into international markets. The company provided guidance for 2025, estimating sales between $997 million and $1.007 billion while acknowledging the impact of certain non-cash charges on financial performance.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table D ($'s in thousands) Three Months Ended September 30, Nine months ended
Tandem Diabetes Care, Inc. has announced its financial results for the third quarter of 2024, reporting a significant increase in GAAP sales by 31% to $244.0 million compared to the same period in 2023. The company also experienced a growth of over 25% in worldwide pump shipments and achieved a positive Adjusted EBITDA. Additionally, it has raised its full-year sales guidance for 2024 while reaffirming other financial forecasts. The company completed a clinical study to expand the Control-IQ indication for type 2 diabetes.
Read more →TNDMTANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Tandem Diabetes Care, Inc. on behalf of long-term stockholders due to a class action complaint alleging fiduciary breaches. This complaint arises from misleading information regarding projected revenues for the year 2022. The firm's investigation focuses on potential misconduct by the board, particularly following a significant downward revision of revenue forecasts that led to a major drop in stock price. Investors have been urged to communicate with the firm regarding their rights and the ongoing investigation.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table D ($'s in thousands) Three Months Ended June 30, Six months ended
Tandem Diabetes Care, Inc. reported their second quarter 2024 financial results, showing a 13% increase in worldwide GAAP sales compared to the previous year. The company successfully launched Tandem Mobi, integrating with the Dexcom G7 continuous glucose monitoring system. They have also completed enrollment for a pivotal study to expand the Control-IQ technology's indications. Furthermore, they raised their full-year 2024 sales guidance to reflect strong performance and high customer retention rates.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table E ($'s in thousands) Three Months Ended
Tandem Diabetes Care, Inc. reported a successful first quarter for 2024, with a 13% increase in worldwide GAAP sales compared to the previous year, reaching $191.7 million. The company has launched new products and expanded FDA indications, contributing to positive market performance. Despite these gains, Tandem acknowledges ongoing operational losses and complexities associated with their Tandem Choice program, which impacted financial reporting. The company has updated its financial guidance, forecasting non-GAAP sales for the year to be approximately $868 million.
Read more →TNDMAbout Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes mana
Tandem Diabetes Care, Inc. announced a proposed private placement of $250 million in Convertible Senior Notes due 2029, aimed at qualified institutional buyers. The offering includes an option for an additional $37.5 million in notes. Proceeds will be utilized for various purposes, including repurchasing existing convertible notes and common stock. However, the company acknowledges that market conditions will play a critical role in the offering's execution.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table E ($'s in thousands) Three Months Ended December 31, Twelve Months Ended
Tandem Diabetes Care, Inc. reported its financial results for Q4 and full year 2023, showcasing both achievements and challenges. The company introduced several new products, including Tandem Mobi and the Tandem Source management platform. However, despite positive sales growth and product launches, they faced substantial GAAP operating and net losses. Moving forward, Tandem anticipates revenue growth in 2024, estimating non-GAAP sales at approximately $850 million for the year.
Read more →TNDM▲ +6.2%on this news
Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline
Tandem Diabetes Care, Inc. is facing a lawsuit due to allegations it misled investors regarding its 2022 sales forecasts. Originally projecting sales between $835 million and $845 million, the company revised its forecast downward to $800 to $805 million, citing increased competition and economic challenges. This significant change led to a sharp decline in the company's stock price by over 28%. The Portnoy Law Firm is encouraging affected investors to contact them for assistance in recovering their losses from the allegations during the class period.
Read more →TNDM▼ -14.4%on this newsshared move
Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline.
The Portnoy Law Firm is advising investors of Tandem Diabetes Care, Inc. to join a lawsuit due to significant declines in the company's stock following a downward revision in its sales forecast for 2022. The lawsuit claims that the company misled investors about its expected sales, initially projecting them between $835 million and $845 million but later revising this to between $800 million and $805 million. This revision is attributed to heightened competition and economic challenges, resulting in a sharp fall in Tandem's stock price. Investors are encouraged to contact the law firm for potential recovery of their losses.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table E ($'s in thousands) Three Months Ended September 30, Nine Months Ended
Tandem Diabetes Care, Inc. reported its financial results for Q3 2023, highlighting an 11% increase in its installed customer base to approximately 444,000. The company announced positive data regarding its t slim X2 with Control-IQ technology and the initial release of Tandem Mobi in the U.S. However, the company still faced financial challenges, including a GAAP operating loss and disruptions reported by distribution partners. Despite these challenges, Tandem reaffirmed its sales guidance for both U.S. and international markets.
Read more →TNDMTANDEM ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Tandem Diabetes Care, Inc. in the U.S. District Court for the Southern District of California. The lawsuit pertains to alleged misleading information regarding the company’s revenue projections for 2022, which were substantially revised downward after initial optimistic forecasts. As a result, Tandem's stock experienced a significant drop of 30.4%. Investors have until November 7, 2023, to apply for lead plaintiff status in the lawsuit, emphasizing potential financial impacts on those who purchased shares during the specified period.
Read more →TNDMTandem Diabetes Care, Inc. Investors: Lead Plaintiff Deadline is Approaching in the Class Action Against Tandem Diabetes Care, Inc.; Contact Robbins LLP Today
A class action has been initiated against Tandem Diabetes Care, Inc. for allegedly misleading investors regarding its 2022 revenue forecasts. The lawsuit claims that Tandem provided inflated revenue projections, which were later revised downward in November 2022, causing significant stock price declines. The case highlights potential negligence in communications to shareholders and examines the impact of competitive and macroeconomic factors on the company's performance. Interested shareholders have until November 7, 2023, to file as lead plaintiffs in the litigation.
Read more →TNDM▼ -6.1%on this news
TANDEM DIABETES CARE, INC. (NASDAQ: TNDM) DEADLINE ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc.
Bernstein Liebhard LLP has announced a deadline for filing a lead plaintiff motion in a securities class action lawsuit against Tandem Diabetes Care, Inc., for investors who purchased shares during a specified period in 2022. The lawsuit alleges serious violations of the Securities Exchange Act, claiming that the company and its officers misled investors regarding revenue projections. Tandem's stock suffered a significant decline following a revised earnings forecast, attributing the change to competitive pressures and economic challenges. Investors are encouraged to discuss their legal rights related to this class action lawsuit before the November 7, 2023, deadline.
Read more →TNDMTandem Diabetes Care, Inc. (TNDM) Investor Alert: Robbins LLP Reminds Investors of Class Action Filed Against Tandem Diabetes Care, Inc.
Robbins LLP has reminded investors of a class action against Tandem Diabetes Care, Inc. regarding allegations of misleading information related to revenue projections. The lawsuit claims that Tandem provided inflated sales estimates, which were later revised downwards, causing a sharp decline in stock price. This class action represents shareholders who purchased TNDM securities within a specific timeline. The case highlights concerns about the company's communication to investors and its implications amidst competitive pressures and macroeconomic challenges.
Read more →TNDMTANDEM DIABETES CARE, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
Bernstein Liebhard LLP has announced a securities class action lawsuit against Tandem Diabetes Care, Inc., alleging that the company and certain officers misled investors regarding sales forecasts during the class period from August 3 to November 2, 2022. The lawsuit claims that the anticipated annual sales of $835 to $845 million were materially misleading, as the company later revised its projections downward to $800 to $805 million. This revision, attributed to competition and macroeconomic factors, led to a significant drop in Tandem's stock price.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table E ($'s in thousands) Three Months Ended June 30, Six Months Ended
Tandem Diabetes Care, Inc. reported its financial results for Q2 2023, highlighting a 16% increase in its worldwide installed base to approximately 437,000 customers. The company launched the Tandem Source application and secured FDA clearance for its new insulin delivery system, Tandem Mobi. However, Tandem reported an increase in GAAP operating losses, which rose to $38.8 million, and cautioned that sales visibility may be affected by the rollout of new products. The company has updated its financial guidance for the remainder of 2023, estimating non-GAAP sales to reach at least $785 million.
Read more →TNDMForward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
media tandemdiabetes.com IR tandemdiabetes.com Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook SAN DIEGO - January 10, 2023 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a global insulin delivery and diabetes technology company, today re
Read more →TNDM▼ -5.4%on this news
Forward Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
media tandemdiabetes.com IR tandemdiabetes.com Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical Acquisition Expands Addressable Market Opportunity and Complements Family of Insulin Delivery Offerings Conference Call Tuesday, December 13, 2022 at 8 00
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table E (in thousands) Three Months Ended June 30, Six Months Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces Second Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance San Diego, August 3, 2022 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a global insulin delivery and diabetes t
Read more →TNDM▼ -6.9%on this news
About Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their love
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Welcomes Two New Members to Board of Directors San Diego, June 16, 2022 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a global insulin delivery and diabetes technology company, today announced the appointmen
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table E (in thousands) Three Months Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces First Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance San Diego, May 4, 2022 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading global insulin delivery and diabet
Read more →TNDMTANDEM DIABETES CARE, INC. Table E Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) (in thousands) Three Months Ended December 31, Year Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance San Diego, February 22, 2022 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes t
Read more →TNDMIn addition to the t connect mobile app being the first to receive FDA clearance on both iOS and Android operating systems to deliver insulin from a personal smartphone, Tandem was also the first to receive an interopera
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces FDA Clearance for the t slim X2 Insulin Pump to Bolus Using the t connect Mobile App First Smartphone App FDA cleared for Insulin Delivery on Both iOS and Android Operating Systems San Diego, Fe
Read more →TNDMReconciliation of GAAP versus Non-GAAP Financial Results (in thousands) Three Months Ended September 30, Nine Months Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces Third Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance Virtual R D Day Scheduled for December 6, 2021 San Diego, November 3, 2021 - Tandem Diabetes Care, Inc. (NASDAQ TN
Read more →TNDMReconciliation of GAAP versus Non-GAAP Financial Results (in thousands) Three Months Ended June 30, Six Months Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces Second Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance San Diego, August 4, 2021 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes tech
Read more →TNDMReconciliation of GAAP versus Non-GAAP Financial Results (in thousands) Three Months Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces First Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance San Diego, May 5, 2021 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes technolo
Read more →TNDMReconciliation of GAAP versus Non-GAAP Financial Results (in thousands) Three Months Ended December 31, Year Ended
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Announces Fourth Quarter and Full Year 2020 Financial Results and 2021 Financial Guidance San Diego, February 24, 2021 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes t
Read more →TNDMAbout Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com ) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors San Diego, December 14, 2020 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer thesabicergroup.com Investor Contact Susan Morrison 858-366-6900 x7005 IR tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Appoints Peyton Howell to Board of
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Appoints Peyton Howell to Board of Directors San Diego, July 29, 2020 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment
Read more →TNDMThe t connect mobile app is intended to be a secondary display for compatible Tandem Diabetes Care insulin pumps and is capable of wirelessly uploading pump data it receives into the t connect web application. The t conn
Tandem Diabetes Care Acquires Sugarmate, a Popular Mobile App for People with Diabetes San Diego, CA - June 24, 2020 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes technology company, today announced its acquisition of Sugarmate, a popular mo
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer thesabicergroup.com Investor Contact Susan Morrison 858-366-6900 x7005 IR tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goe
ssabicer thesabicergroup.com IR tandemdiabetes.com Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors San Diego, June 4, 2020 - Tandem Diabetes Care, Inc. (NASDAQ TNDM), a leading insulin delivery and diabetes technology company, today announced th
Read more →TNDMInclude for base capped call. 2 Include for additional capped call. 3 Include for base capped call. 4 Include for additional capped call. 5 Include for base capped call. 6 Include for additional capped call. 7 To be Deal
To Tandem Diabetes Care, Inc. 11075 Roselle Street San Diego, California 92121 Attention David B. Berger, Esq. Telephone No. (858) 255-6380 A C From Dealer Re Base Additional Call Option Transaction Ref. No Insert Reference Number Date May 15 , 2020 Dear Ladies and Gentlemen T
Read more →TNDM1. As measured by CGM 2. If glucose alerts and CGM readings do not match symptoms or expectations or if taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose mete
Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology Automated Insulin Dosing Software First to Receive New Classification by FDA San Diego, CA - December 13, 2019 - Tandem Diabetes Care, Inc. (NASDAQ
Read more →TNDMTANDEM DIABETES CARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (Unaudited) Three Months Ended September 30, Nine Months Ended
ssabicer@thesabicergroup.com IR@tandemdiabetes.com Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance San Diego, November 4, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technolo
Read more →TNDMTANDEM DIABETES CARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (Unaudited) Three Months Ended June 30, Six Months Ended
ssabicer@thesabicergroup.com IR@tandemdiabetes.com Tandem Diabetes Care Announces Second Quarter 2019 Financial Results and Updated 2019 Financial Guidance San Diego, August 1, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technolog
Read more →TNDMTandem Diabetes Care Reports Positive Results from Two Studies of the t:slim X2 Insulin Pump with Control-IQ Technology Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age
Tandem Diabetes Care Reports Positive Results from Two Studies of the t:slim X2 Insulin Pump with Control-IQ Technology Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups San Francisco, CA - June 9, 2019 - Tandem Diabetes Care, Inc. (NASDAQ:
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2019 Fin
ssabicer@thesabicergroup.com IR@tandemdiabetes.com Tandem Diabetes Care Announces First Quarter 2019 Financial Results and Updated 2019 Financial Guidance San Diego, April 30, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports 2018 Financial Results a
ssabicer@thesabicergroup.com IR@tandemdiabetes.com Tandem Diabetes Care Reports 2018 Financial Results and 2019 Financial Guidance San Diego, February 26, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today report
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Appointment of
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Appointment of Rebecca Robertson as Board Member San Diego, January 3, 2019 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports Third Quarter 201
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Reports Third Quarter 2018 Financial Results San Diego, November 1, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its
Read more →TNDMTandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results Continued Domestic Demand and International Launch of the t:slim X2 Insulin Pump Drive Growth Sa
Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results Continued Domestic Demand and International Launch of the t:slim X2 Insulin Pump Drive Growth San Diego, September 25, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medi
Read more →TNDMTandem Diabetes Care Announces Full Repayment of Outstanding CRG Debt San Diego
Tandem Diabetes Care Announces Full Repayment of Outstanding CRG Debt San Diego - August 8, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, to
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Closing of $115
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Closing of $115 Million Underwritten Public Offering of Common Stock San Diego, August 7, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), ("Tandem") a medical device company and manufac
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports Second Quarter 20
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Reports Second Quarter 2018 Financial Results San Diego, July 30, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pump av
Read more →TNDMTandem Diabetes Care Announces FDA Approval of t:slim X2 Insulin Pump with Basal-IQ Technology New Predictive Low Glucose Suspend Feature to Launch with Dexcom G6 CGM System Integration San Diego, C
Tandem Diabetes Care Announces FDA Approval of t:slim X2 Insulin Pump with Basal-IQ Technology New Predictive Low Glucose Suspend Feature to Launch with Dexcom G6 CGM System Integration San Diego, CA - June 21, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device
Read more →TNDMTandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump San Diego
Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump San Diego, April 30, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced receipt of CE mark approval for the t:slim X2
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports First Quarter 201
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Reports First Quarter 2018 Financial Results San Diego, April 26, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps a
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Preliminary Fir
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results San Diego, April 10, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pum
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces 2017 Financial
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces 2017 Financial Results San Diego, March 1, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in t
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Closing of $69
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Closing of $69 Million Underwritten Public Offering of Common Stock San Diego, February 13, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Pricing of $60
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock San Diego, February 9, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of t
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Preliminary 201
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance Guidance for 2018 Reflects Expectation of Continued Growth San Diego, January 09, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Commences Full Manufactur
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Commences Full Manufacturing Operations At New San Diego Facility San Diego, January 3, 2018 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touch
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Retirement of C
Media Contact: Steve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment San Diego, December 7, 2017 Tandem Diabetes
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Proposed Underw
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Proposed Underwritten Public Offering of Common Stock, Series A Warrants and Series B Warrants San Diego, October 12, 2017 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device c
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Approval of Rev
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Approval of Reverse Stock Split San Diego, October 9, 2017 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM) previously announced that a proposal was approved at its Special Meeting of Stockhol
Read more →TNDMEx. 99.1 Media Contact: Steve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces FDA Ap
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces FDA Approval and Launch of t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration Software Update Available for Current t:slim X2 Pump Users Via Personal Computer San Diego, August
Read more →TNDMFor the three months ended March 31, 201 7 , the impact of the Upgrade Program was as follows: Impact of Technology Upgrade Program (1) (in millions) GAAP Financial Results Deferrals at Initial Sale 1 Recognition of Defe
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Reports First Quarter 2017 Financial Results San Diego, April 27, 2017 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps a
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Pricing of Unde
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock San Diego, March 23, 2017 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchs
Read more →TNDMEx. 99.1 Media Contact: Steve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports 2016 Fin
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Reports 2016 Financial Results San Diego, March 8, 2017 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the
Read more →TNDMTandem Diabetes Care To Draw Down $35 Million Under Existing Term Loan Facility with
Tandem Diabetes Care To Draw Down $35 Million Under Existing Term Loan Facility with CRG SAN DIEGO, November 29, 2016 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM) today announced that it has initiated the drawdown of $35 million under the company's previously announced term loa
Read more →TNDMSteve Sabicer 714-907-6264 ssabicer@thesabicergroup.com Investor Contact: Susan Morrison 858-366-6900 x7005 smorrison@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Now Shipping Next-Generat
ssabicer@thesabicergroup.com smorrison@tandemdiabetes.com Tandem Diabetes Care Now Shipping Next-Generation t:slim X2 Insulin Pump San Diego, October 24, 2016 - Tandem Diabetes Care , Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insuli
Read more →TNDMTandem Diabetes Care to Present at the 27th Annual Piper Jaffray Healthcare Conference
Tandem Diabetes Care, Inc. will present at the 27th Annual Piper Jaffray Healthcare Conference on December 1, 2015. CEO Kim Blickenstaff will provide a company update during the presentation, which will be available via live webcast. The company is known for its innovative insulin pump products designed for diabetes management.
Read more →TNDMTandem Diabetes Care to Present at the Stifel 2015 Healthcare Conference
Tandem Diabetes Care, Inc. will present at the Stifel 2015 Healthcare Conference on November 18, 2015. CEO Kim Blickenstaff will provide a company update during the live webcast. The event highlights the company's innovative insulin pump products and commitment to diabetes management.
Read more →TNDMTandem Diabetes Care Schedules Third Quarter 2015 Earnings Press Release and Conference Call
Tandem Diabetes Care, Inc. plans to release its third quarter 2015 financial results on October 29, 2015. A conference call and webcast will follow the release to discuss the results. The company is known for its innovative insulin pumps designed for diabetes management.
Read more →TNDMTandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. announced that CEO Kim Blickenstaff will present at upcoming investor conferences. The presentations will be available via live webcast and archived for 30 days. This initiative reflects the company's commitment to keeping investors informed about its innovative diabetes management products.
Read more →TNDMTandem Diabetes Care to Present at the 2015 Wedbush PacGrow Healthcare Conference
Tandem Diabetes Care, Inc. will present a company update at the 2015 Wedbush PacGrow Healthcare Conference. CEO Kim Blickenstaff is scheduled to speak on August 11, 2015, at 1:20 PM ET. The presentation will be available via live webcast and archived for 30 days on their Investor Center website.
Read more →TNDMTandem Diabetes Care Schedules Second Quarter 2015 Earnings Press Release and Conference Call
SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (NASDAQ:TNDM), a medical device company and manufacturer of the t:slim and t:flex Insulin Pumps, plans to release its second quarter 2015 results after the financial markets close on Thursday, July 30, 2015.
Read more →TNDMTandem Diabetes Care Schedules First Quarter 2015 Earnings Press Release and Conference Call
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim and t:flex Insulin Pumps, plans to release its first quarter 2015 results after the financial markets close on Thursday, April 30, 2015
Read more →TNDMTandem Diabetes Care to Present at the Cowen and Company 35th Annual Health Care Conference
Tandem Diabetes Care, Inc. will present at the Cowen and Company 35th Annual Health Care Conference. CEO Kim Blickenstaff will provide a company update on March 3, 2015. The presentation will be available via live webcast and archived for 30 days. Tandem specializes in innovative insulin pump technology for diabetes management.
Read more →TNDMTandem Diabetes Care Schedules Fourth Quarter and Full Year 2014 Earnings Press Release and Conference Call
SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim and t:flex Insulin Pumps, plans to release its fourth quarter and full year 2014 results after the financial markets close on Tuesday, F
Read more →TNDMTandem Diabetes Care to Present at Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 19, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Piper Jaffray Healthcare Co
Read more →TNDMTandem Diabetes Care to Present at Stifel Healthcare Conference
SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Stifel Healthcare Conference
Read more →TNDMTandem Diabetes Care Announces Schedule Change for Third Quarter 2014 Earnings Press Release and Conference Call
SAN DIEGO, Oct. 24, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, today announced a schedule change for its third quarter 2014 results. The company will now release its third quarter 2014
Read more →TNDMTandem Diabetes Care Schedules Third Quarter 2014 Earnings Press Release and Conference Call
SAN DIEGO, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, plans to release its third quarter 2014 results after the financial markets close on Thursday, November 6, 2014. The Compa
Read more →TNDMTandem Diabetes Care Schedules Second Quarter 2014 Earnings Press Release and Conference Call
SAN DIEGO, July 16, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, plans to release its second quarter 2014 results after the financial markets close on Thursday, July 31, 2014. The Company
Read more →TNDMTandem Diabetes Care Announces Schedule Change for Deutsche Bank 39th Annual Health Care Conference Presentation
SAN DIEGO, May 2, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, today announced a schedule change for its presentation at the Deutsche Bank 39th Annual Health Care Conference at the InterC
Read more →TNDMTandem Diabetes Care Schedules First Quarter 2014 Earnings Press Release and Conference Call
SAN DIEGO, April 23, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, plans to release its first quarter 2014 results after the financial markets close on Tuesday, May 6, 2014. The Company wi
Read more →TNDMTandem Diabetes Care and Capital Royalty Amend and Restate Term Loan Facility
SAN DIEGO, April 9, 2014 (GLOBE NEWSWIRE) -- Tandem Diabetes Care , Inc. (Nasdaq:TNDM) and Capital Royalty Partners II, L.P. and its affiliate funds ("Capital Royalty") today announced that they have amended and restated the term loan facility under which the Company borrowed $30
Read more →Competitive Position
How TNDM ranks across every disease it competes inCompetitive Position is a premium feature
See how TNDM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial